Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis

Summary.  Aim: To determine if the mode of presentation of venous thromboembolism (VTE), as deep vein thrombosis (DVT) or pulmonary embolism (PE), predicts the likelihood and type of recurrence. Methods: We carried out a patient‐level meta‐analysis of seven prospective studies in patients with a first VTE who were followed after anticoagulation was stopped. We used Kaplan‐Meier analysis to determine the cumulative incidence of recurrent VTE according to mode of presentation, and multivariable Cox regression to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for mode of and extent of DVT as potential risk factors for recurrence. Results: The 5‐year cumulative rate of recurrent VTE in 2554 patients was 22.6%. In 869 (36.1%) patients with PE, the 5‐year rate of any recurrence (DVT or PE) was 22.0%, and recurrence as PE was 10.6%. In 1365 patients with proximal DVT, the 5‐year recurrence rate was 26.4%, and recurrence with PE was 3.6%. The risk of recurrence as PE was 3.1‐fold greater in patients presenting with symptomatic PE than in patients with proximal DVT (HR, 3.1; 95% CI, 1.9–5.1). Patients with proximal DVT had a 4.8‐fold higher cumulative recurrence rate than those with distal DVT (HR, 4.8; 95% CI, 2.1–11.0). Conclusion: Whilst DVT and PE are manifestations of the same disease, the phenotypic expression is predetermined. Patients presenting with PE are three times more likely to suffer recurrence as PE than patients presenting with DVT. Patients presenting with calf DVT are at low risk of recurrence and at low risk of recurrence as PE.

[1]  Rebecca Tooher,et al.  Extending an evidence hierarchy to include topics other than treatment: revising the Australian 'levels of evidence' , 2009, BMC medical research methodology.

[2]  J. Douketis,et al.  Systematic Review: d-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism , 2008, Annals of Internal Medicine.

[3]  G. Raskob,et al.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[4]  R. Abbate,et al.  Combination of D‐dimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal , 2008, Journal of thrombosis and haemostasis : JTH.

[5]  C. Palmer,et al.  Unprovoked recurrent venous thrombosis: prediction by D‐dimer and clinical risk factors , 2008, Journal of thrombosis and haemostasis : JTH.

[6]  S. Laporte,et al.  Thromboembolism : Findings From the Registro Informatizado de la Enfermedad Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous , 2008 .

[7]  J. Ansell.  Factor Xa or thrombin: is factor Xa a better target? , 2007, Journal of thrombosis and haemostasis : JTH.

[8]  A. Iorio,et al.  D-dimer testing to determine the duration of anticoagulation therapy. , 2006, The New England journal of medicine.

[9]  P. Ridker,et al.  D‐dimer, factor VIII coagulant activity, low‐intensity warfarin and the risk of recurrent venous thromboembolism , 2006, Journal of thrombosis and haemostasis : JTH.

[10]  Paolo Prandoni,et al.  Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.

[11]  O. Wagner,et al.  D-dimer levels and risk of recurrent venous thromboembolism. , 2003, JAMA.

[12]  F. Bernardi,et al.  Predictive Value of D‐Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia , 2003, Circulation.

[13]  C. Kearon,et al.  Natural History of Venous Thromboembolism , 2003, Circulation.

[14]  P. Romano,et al.  Comparison of Outcomes after Hospitalization for Deep Venous Thrombosis or Pulmonary Embolism , 2002, Thrombosis and Haemostasis.

[15]  Douglas G Altman,et al.  Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.

[16]  I. Durieu,et al.  Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis , 2001, Circulation.

[17]  M. Prins,et al.  Is the Prevalence of the Factor V Leiden Mutation in Patients with Pulmonary Embolism and Deep Vein Thrombosis Really Different? , 1999, Thrombosis and Haemostasis.

[18]  L. Melton,et al.  Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. , 1999, Archives of internal medicine.

[19]  J. Douketis,et al.  Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. , 1998, JAMA.

[20]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[21]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.

[22]  S. Schulman,et al.  A Comparison of Six Weeks With Six Months of Oral Anticoagulant Therapy After a First Episode of Venous Thromboembolism , 1996 .

[23]  R. Hull,et al.  Antithrombotic therapy for venous thromboembolic disease. , 1995, Chest.

[24]  M. Monreal,et al.  Recurrent pulmonary embolism in patients treated because of acute venous thromboembolism: a prospective study. , 1994, European journal of vascular surgery.

[25]  J. Birkmeyer,et al.  The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. , 1994, Archives of internal medicine.